An Open-label Extension Study of Aficamten for Chinese Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-week Results

Cytokinetics Incorporated published this content on April 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2026 at 21:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]